BEONE MEDICINES - BeiGene Co., Ltd.’s cautionary announcement regarding changes in the equity of shareholders holding more than 5% of shares touching the 1% mark
BEONE MEDICINES - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.
BeOne Medicines Ltd. BeiGene Co., Ltd.
(Company incorporated under Swiss law) (Stock code: 06160)
Overseas regulatory announcement
This announcement is made by BeOne Medicines Ltd. (the "Company") pursuant to the Hong Kong Joint Stock Exchange Made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities of Hong Kong Limited.
This is to set forth the company's "Regarding the Shareholding of More than 5% of BeiGene Co., Ltd." published on the website of the Shanghai Stock Exchange. "Indicative Announcement on Changes in Shareholders' Equity Touching the 1% Scale" is for reference only.
By order of the board of directors BeiGene Co., Ltd.
Chairman Mr. Olejian
Hong Kong, June 1, 2026
As at the date of this announcement, the Company’s Board of Directors includes Mr. Ou Leqiang, Chairman and Executive Director, and Mr. Wang Wang, Non-executive Director. Dr. Xiaodong, as well as independent non-executive directors Dr. Olivier Brandicourt and Margaret Han Dugan Dr. Michael Goller, Anthony C. Hooper, Ranjeev Krishana,
Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Yi Mr. Qingqing.
A-share code code: 688235 A-share abbreviation: Baekje Jishenzhou Announcement No.: 2026-018
Hong Kong stock code: 06160 Hong Kong stock abbreviation: Baiji Jishenzhouzhou
U.S. stock code:: ONC
Baibaiji Jishenzhou Co., Ltd.
Regarding changes in equity interests of the above shareholders holding shares 5%
Touch and mark reminders and announcements 1%
The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading information.
sexual statements or major omissions, and shall be legally responsible for the authenticity, accuracy and completeness of its contents.
legal responsibility.
Important content reminder: Direction of equity change Increase in proportion Decrease in proportion ☐ ☑ Total ratio before changes in equity 17.01% Total ratio after changes in equity 16.70% Does this change violate the promise made? Yes No promise, intention, plan ☐ ☑ Whether the mandatory tender offer obligation is triggered? Yes No ☐ ☑
Information disclosure obligations: Everyone has the obligation to disclose and act in concert with everyone’s basic information.
Identity Category
Controlling shareholder/actual controller and persons acting in concert ☐ Other major shareholders with more than 5% and their persons acting in concert ☑ Identity of investors and their persons acting in concert The largest shareholder and its persons acting in concert (only applicable ☐ (With no controlling shareholder or actual controller) Other ______________ (please specify) ☐
- Information of information disclosure obligor
Name of information disclosure obligor Identity of investor Unified social credit code
Controlling shareholder/actual controller ☐ Consistency of controlling shareholder/actual controller AmgenInc. ☐ Not applicable ☑ man of action Other direct shareholders ☑
- Basic situation of changes in equity interests touching a 1% tick mark
BG NC 2, Ltd., a subsidiary of BeiGene Co., Ltd. (hereinafter referred to as the "Company"), in 2026
On May 29 (US Eastern Time), 27,300,000 common shares of the company were transferred to the company's custodian company,
In exchange for a corresponding number of American depositary shares (each American depositary share is equivalent to 13 ordinary shares), the purpose is
In ensuring that its custodian company can use the American depositary shares at any time to redeem the company’s options and incentives under the 2016 The equity awards granted to the incentive objects under the plan (as revised from time to time) and yet to be cashed in (hereinafter referred to as "this issuance")
OK OK"). This issuance does not involve changes in the number of A shares of the company.
Before and after this issuance, the number of shares held by Amgen Inc., a shareholder holding more than 5% of the company's shares, remained unchanged. The number of shares remained unchanged at 246,269,426 shares, and the shareholding ratio changed from 17.01% to 16.70% (hereinafter referred to as
"Changes in equity interests this time"), the equity change touches 1%, the equity changes this time are as follows:
Changes in equity Investor name Number of shares before change Ratio before change Number of shares after change Ratio after change Time zone of equity change method Name (10,000 shares) Example (%) (10,000 shares) Example (%) room Entities with direct shareholding changes: centralized bidding ☐ AmgenInc. 24,626.9426 17.01 24,626.9426 16.70 Block Transaction 2026/5/29 ☐ Others: Passive rare Explanation (please specify)
Total 24,626.9426 17.01 24,626.9426 16.70 -- --
Note: Amgen Inc.’s shareholding information is based only on information filed with the U.S. Securities and Exchange Commission.
Disclosure of information contained in documents.
Other explanations
This change in equity does not involve a tender offer, nor will it result in the company having no controlling shareholder or actual control.
The control status changes.
- This equity change does not involve the company’s shareholders’ disclosure of equity change reports, acquisition reports, and offers.
Acquisition report and other documents.
Announcement is hereby made.
BeiGene Co., Ltd. Board of Directors
June 2, 2026